SCHEMBL15919659

SCHEMBL15919659

CC(C)(C)OC(=O)NNC(=O)c1cc(-c2ccc(-c3ccc(CC(=O)N4CCOCC4)cc3)cc2)nc2ccncc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.44
LMNA P02545 3/20 0.44
ACACB O00763 3/20 0.43
ACACA Q13085 2/20 0.43
NPC1 O15118 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 4/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 5/20 0.42
HPGD P15428 3/20 0.42
HSD17B10 Q99714 3/20 0.42
TSHR P16473 2/20 0.42
POLB P06746 2/20 0.42
USP2 O75604 1/20 0.42
TP53 P04637 1/20 0.42
GPR55 Q9Y2T6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15919450 0.89 L3MBTL1 (0.48) KDM4ELMNAACACBACACANPC1
SCHEMBL15919457 0.87 ALDH1A1 (0.45) KDM4ELMNAACACBACACANPC1
SCHEMBL15919672 0.86 MAPT (0.47) KDM4ELMNANPC1CYP3A4CYP2C9
SCHEMBL15904995 0.85 MAPT (0.50) KDM4ELMNANPC1CYP3A4CYP2C9
Hydrochloric Acid SCHEMBL15905149 0.84 MAPT (0.49) KDM4ELMNANPC1CYP3A4CYP2C9
SCHEMBL15919445 0.84 MAPT (0.48) KDM4ELMNAACACBACACACYP3A4
SCHEMBL15905078 0.80 MEN1 (0.51) KDM4ELMNAACACBACACANPC1
SCHEMBL15919508 0.79 ACACB (0.48) KDM4EACACBACACANPC1CYP3A4
SCHEMBL15919262 0.79 ACACB (0.46) KDM4EACACBACACANPC1CYP3A4
SCHEMBL15919419 0.78 ACACB (0.44) KDM4EACACBACACANPC1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO KDM4E 3322/4885LMNA 4266/4885ACACB 1141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.